Form 6-K Galmed Pharmaceuticals For: Aug 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Galmed Pharma (GLMD) Misses Q2 EPS by 4c
August 3, 2016 8:51 AM EDTGalmed Pharma (NASDAQ: GLMD) reported Q2 EPS of ($0.39), $0.04 worse than the analyst estimate of ($0.35).
For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.
... More